First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
Abstract Dysregulation of the mineralocorticoid hormone aldosterone is an increasingly prevalent cause of hypertension. Aldosterone synthase (CYP11B2) shares 93% homology to 11β‐hydroxylase (CYP11B1), which produces cortisol. Lorundrostat, a highly selective inhibitor of CYP11B2, is a potential safe...
Saved in:
Main Authors: | Hidetoshi Shimizu (Author), Michael A. Tortorici (Author), Yoshiyasu Ohta (Author), Kei Ogawa (Author), Sheikh Mohammed Ashfaq Rahman (Author), Aya Fujii (Author), Yuki Hiraga (Author), Mizue Kawai (Author), Kanami Sugimoto‐Kawabata (Author), Mattheus (Thijs) (Author), Jan Jaap vanLier (Author), Stephen Djedjos (Author), B. T. Slingsby (Author), David M. Rodman (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baxdrostat and finerenone: new aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system inhibitors for the drug treatment of resistant arterial hypertension
by: O. B. Kuzmin, et al.
Published: (2024) -
Diuretic effects of Hecogenin and Hecogenin acetate via aldosterone synthase inhibition
by: Abdulmohsin J. Alamoudi, et al.
Published: (2024) -
Primary Aldosteronism and Pregnancy
by: Tomáš Zelinka, et al.
Published: (2020) -
Primary aldosteronism and pregnancy
by: V.I. Medved, et al.
Published: (2022) -
Renin-Angiotensin Aldosterone System
Published: (2021)